Basilea Pharmaceutica (BSLN) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Basilea Pharmaceutica CH:BSLN is currently developing the following drugs: Oral Fosmanogepix, Iv Fosmanogepix, Fosmanogepix Iv Infusion, Standard Of Care Antifungal Therapy, Fosmanogepix Oral Tablet, Pitavastatin, Pitavastatin Single Dose Combined With Ceftobiprole, Esomeprazole, Ceftibuten, Ledaborbactam Etzadroxil, Ceftibuten-Ledaborbactam Etzadroxil, Ceftibuten, Ledaborbactam Etzadroxil, Ceftobiprole Medocaril, Fosmanogepix, Apx001, Apx001a, Fluconazole, Fosmanogepix, Caspofungin, Derazantinib, Derazantinib-Paclitaxel-Ramucirumab Combination, [14C]-Apx001 Oral Solution, [14C]-Apx001 Solution For Infusion, Rifampin, Itraconazole, Apx001, Apx001, Derazantinib Capsule, [14C]-Derazantinib Solution For Infusion, [14C]-Derazantinib Capsule, Derazantinib 300 Mg Once Daily Monotherapy, Derazantinib 200 Mg Once Daily + Atezolizumab 1200 Mg, Derazantinib 300 Mg Once Daily+ Atezolizumab 1200 Mg, Derazantinib 200 Mg Twice Daily + Atezolizumab 1200 Mg, Derazantinib 300 Mg Once Daily + Atezolizumab 1200 Mg, Derazantinib 200 Mg Twice Daily Monotherapy, Ceftobiprole Medocaril, Iv Standard-Of-Care Cephalosporin, Apx001 With Standard Of Care Anti-Fungal Agent, Isavuconazonium Sulfate - Intravenous, Isavuconazonium Sulfate - Oral, Radiation Therapy, Microtubule-Targeted Agent Bal101553, Derazantinib, Ceftobiprole Medocaril, Vancomycin+Aztreonam, Ceftobiprole Medocaril, Daptomycin, Apx001 Single Dose 1, Apx001 Single Dose 2, Apx001 Single Dose 3, Apx001 Single Dose 4, Apx001 Single Dose 5, Apx001 Single Dose 6, Apx001 Multiple Dose 1, Apx001 Multiple Dose 2, Apx001 Multiple Dose 3, Apx001 Multiple Dose 4, Apx001 Single Iv Dose, Apx001 Single Oral Dose 1, Apx001 Single Oral Dose 2, Apx001 Single Oral Dose 3, Apx001 Single Oral Dose Fasted, Apx001 Single Oral Dose Fed, Apx001 Multiple Oral Doses 1, Apx001 Multiple Oral Doses 2, Apx001 Multiple Oral Doses 3, Cytochrome P450 Substrates, Bal101553, Bal101553 At Mtd, Lisavanbulin Phase 1 Dose Escalation Portion, Lisavanbulin Phase 2A Expansion Portion, Derazantinib Low Dose Range, Derazantinib Middle Dose Range, Derazantinib High Dose Range, Derazantinib At Recommended Phase 2 Dose, Bal101553, Alitretinoin, Isavuconazole, Voriconazole, Isavuconazole, Caspofungin, Voriconazole, Isavuconazole. These drug candidates are in various stages of clinical development as the company works toward FDA approval.